Revolution Medicines, Inc.
RVMD
$76.76
$1.451.92%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 1,272.51% | -90.70% | |||
| Gross Profit | -1,272.51% | 90.70% | |||
| SG&A Expenses | 30.02% | 15.91% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 19.10% | 9.95% | |||
| Operating Income | -19.10% | -9.95% | |||
| Income Before Tax | -23.17% | -16.11% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -23.17% | -16.11% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -23.17% | -16.11% | |||
| EBIT | -19.10% | -9.95% | |||
| EBITDA | -19.15% | -9.95% | |||
| EPS Basic | -22.76% | -15.83% | |||
| Normalized Basic EPS | -22.75% | -15.84% | |||
| EPS Diluted | -22.76% | -15.83% | |||
| Normalized Diluted EPS | -22.75% | -15.84% | |||
| Average Basic Shares Outstanding | 0.34% | 0.23% | |||
| Average Diluted Shares Outstanding | 0.34% | 0.23% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||